BioPharma Dive: Brain disease startup Neumora draws more funding for ambitious research plan Read More
Endpoints: The Endpoints 11: The top private biotechs in pursuit of new drugs. Pushing the envelope with powerful new technologies Read More
Endpoints: ARCH unveils its Really Big Neuroscience Company with $500M, an Amgen deal and eyes on depression, Alzheimer’s and a lot more Read More
Business Insider: A new startup created by one of biotech’s biggest VCs shows you need to go big to treat brain disorders Read More
Biopharma Dive: Armed with half a billion dollars, a startup aims to change how brain drugs are made Read More